Valence Discovery: transforming AI-enabled drug design

Artificial intelligence (AI) has become an increasingly popular tool for drug companies discovering and designing new therapies. According to analysis by Deloitte, the AI market in drug discovery is expected to grow from $159.8m in 2018 to $2.9bn by 2025. Of the almost 180 start-ups involved in AI-assisted drug discovery in 2019, 40% were working on repurposing existing drugs or generating novel drug candidates using AI, machine learning, and automation. AI-enabled drug design company Valence Discovery, formerly InVivo AI, was founded in 2018. Since its rebrand last month, the company has announced a series of impressive drug discovery and design partnerships, with the aim of making advanced technology accessible to R&D organisations of all sizes.